123 related articles for article (PubMed ID: 10066792)
21. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.
Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1992 Jul; 267(19):13150-3. PubMed ID: 1320012
[TBL] [Abstract][Full Text] [Related]
22. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
23. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC
Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791
[TBL] [Abstract][Full Text] [Related]
24. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
25. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.
Okada Y; Tosaka A; Nimura Y; Kikuchi A; Yoshida S; Suzuki M
Gene; 2001 Jul; 272(1-2):141-8. PubMed ID: 11470519
[TBL] [Abstract][Full Text] [Related]
26. Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIalpha and IIbeta isoforms.
van Hille B; Perrin D; Hill BT
Anticancer Drugs; 1999 Jul; 10(6):551-60. PubMed ID: 10885903
[TBL] [Abstract][Full Text] [Related]
27. Catalysis of ATP hydrolysis by two NH(2)-terminal fragments of yeast DNA topoisomerase II.
Olland S; Wang JC
J Biol Chem; 1999 Jul; 274(31):21688-94. PubMed ID: 10419479
[TBL] [Abstract][Full Text] [Related]
28. Measurement of Drug-Stabilized Topoisomerase II Cleavage Complexes by Flow Cytometry.
de Campos Nebel M; Palmitelli M; González-Cid M
Curr Protoc Cytom; 2017 Jul; 81():7.48.1-7.48.8. PubMed ID: 28678420
[TBL] [Abstract][Full Text] [Related]
29. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
30. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.
Dong J; Walker J; Nitiss JL
J Biol Chem; 2000 Mar; 275(11):7980-7. PubMed ID: 10713116
[TBL] [Abstract][Full Text] [Related]
31. Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.
Bender RP; Osheroff N
Chem Res Toxicol; 2007 Jun; 20(6):975-81. PubMed ID: 17516663
[TBL] [Abstract][Full Text] [Related]
32. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
33. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
34. A Role for VCP/p97 in the Processing of Drug-Stabilized TOP2-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2021 Jul; 100(1):57-62. PubMed ID: 33941661
[TBL] [Abstract][Full Text] [Related]
35. Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.
Rogojina AT; Nitiss JL
J Biol Chem; 2008 Oct; 283(43):29239-50. PubMed ID: 18723844
[TBL] [Abstract][Full Text] [Related]
36. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Nitiss JL; Liu YX; Hsiung Y
Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
[TBL] [Abstract][Full Text] [Related]
37. Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis.
Sim SP; Liu LF
J Biol Chem; 2001 Aug; 276(34):31590-5. PubMed ID: 11406628
[TBL] [Abstract][Full Text] [Related]
38. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions.
Leteurtre F; Fujimori A; Tanizawa A; Chhabra A; Mazumder A; Kohlhagen G; Nakano H; Pommier Y
J Biol Chem; 1994 Nov; 269(46):28702-7. PubMed ID: 7961822
[TBL] [Abstract][Full Text] [Related]
39. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
40. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
